Tirzepatide vs semaglutide for weight loss: what the trials actually support

“Tirzepatide beats semaglutide” is one of the most repeated claims in the weight-loss conversation. It is largely true — but the strength of the evidence depends heavily on which comparison you mean. Most of the numbers people cite come from separate trials with different populations, and only two studies actually randomized patients to one drug versus the other. Getting this distinction right is the whole point.

Why a difference is biologically plausible

Semaglutide is a single-receptor agonist (GLP-1). Tirzepatide is a dual agonist hitting both GLP-1 and GIP receptors. The extra incretin pathway is the mechanistic reason many expected tirzepatide to produce more weight loss — though mechanism alone never settles a clinical question.

The separate pivotal trials (not head-to-head)

In STEP 1, once-weekly semaglutide 2.4 mg produced a mean weight loss of about 14.9% at 68 weeks in adults with obesity and no diabetes.^[1] In SURMOUNT-1, tirzepatide at its highest dose produced mean reductions up to roughly 20.9% at 72 weeks in a comparable population.^[2] Those figures look decisive — but they come from different trials with different participants, durations, and sites. Cross-trial comparison suggests an advantage; it does not prove one.

The head-to-head evidence, part one: SURPASS-2 (diabetes)

The first true randomized comparison was SURPASS-2, in people with type 2 diabetes. Patients were assigned to tirzepatide (5, 10, or 15 mg) or semaglutide 1 mg. Tirzepatide was superior for both HbA1c reduction and weight loss across doses.^[3] Two important caveats: it used the 1 mg diabetes dose of semaglutide (not the 2.4 mg obesity dose), and the population had diabetes — so it does not directly answer the obesity question.

The head-to-head evidence, part two: SURMOUNT-5 (obesity)

SURMOUNT-5 is the trial that finally settled the obesity comparison on fair terms: adults with obesity and no diabetes were randomized to maximum-tolerated tirzepatide versus maximum-tolerated semaglutide 2.4 mg. Tirzepatide produced significantly greater weight loss — roughly 20% versus about 14% — over 72 weeks.^[4] This is the single strongest piece of evidence on the question, because both drugs were used at their obesity doses in the same trial.

What the trials do and don't support

Supported: at obesity doses, in a head-to-head trial, tirzepatide produces more weight loss than semaglutide on average (SURMOUNT-5). Also supported: tirzepatide outperforms 1 mg semaglutide for glycemic control in diabetes (SURPASS-2). Not equivalent to those: the popular STEP-vs-SURMOUNT number comparison, which is suggestive but cross-trial. And nothing here speaks to the comparison that matters most to many patients — long-term cardiovascular outcomes — where semaglutide currently has the larger dedicated outcomes dataset.

The honest bottom line

For average weight loss, the best evidence (SURMOUNT-5) favors tirzepatide. But “more on average” is not “better for you”: tolerability, cost, access, cardiovascular-outcomes data, and individual response all matter, and both drugs share the same gastrointestinal side-effect class. Read the head-to-head trials as the answer to one specific question — mean weight change — not as a verdict on which drug any given person should take.